Despite important progress in the selectivity of the molecules described in this review, the development of more selective pharmacological tools to selectively inhibit each SOC isoform could facilitate the emergence of innovative therapies concerning multiple diseases, including PAH. The gene discussed is UBXN11; the disease is pulmonary arterial hypertension.